Published in Immunology on December 01, 1998
Human T-lymphotropic virus proteins and post-translational modification pathways. World J Virol (2012) 0.79
A system for screening agonists targeting beta2-adrenoceptor from Chinese medicinal herbs. J Zhejiang Univ Sci B (2009) 0.78
A threshold level of NFATc1 activity facilitates thymocyte differentiation and opposes notch-driven leukaemia development. Nat Commun (2016) 0.75
Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature (1994) 9.37
Cyclic AMP and the induction of eukaryotic gene transcription. J Biol Chem (1988) 4.58
Transcriptional regulation by cyclic AMP. Annu Rev Biochem (1997) 3.81
Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction. Proc Natl Acad Sci U S A (1990) 3.69
Control of cAMP-regulated enhancers by the viral transactivator Tax through CREB and the co-activator CBP. Nature (1996) 3.27
Phosphorylation of CREB affects its binding to high and low affinity sites: implications for cAMP induced gene transcription. EMBO J (1992) 2.23
Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood (1995) 2.19
Location of cAMP-dependent protein kinase type I with the TCR-CD3 complex. Science (1994) 1.59
Multiple protein kinase A-regulated events are required for transcriptional induction by cAMP. Proc Natl Acad Sci U S A (1995) 1.35
cAMP antagonizes interleukin 2-promoted T-cell cycle progression at a discrete point in early G1. Proc Natl Acad Sci U S A (1988) 1.30
CD2/LFA-3 ligation induces phospholipase-C gamma 1 tyrosine phosphorylation and regulates CD3 signaling. J Immunol (1992) 1.22
Human T-cell lymphotropic virus type 1 Tax mediates enhanced transcription in CD4+ T lymphocytes. J Virol (1996) 1.22
Irreversible oxidative inactivation of protein kinase C by photosensitive inhibitor calphostin C. FEBS Lett (1992) 1.18
Expression of a peptide inhibitor of protein phosphatase 1 increases phosphorylation and activity of CREB in NIH 3T3 fibroblasts. Mol Cell Biol (1994) 1.17
Transcriptional regulation of the interleukin-2 gene in normal human peripheral blood T cells. Convergence of costimulatory signals and differences from transformed T cells. J Biol Chem (1996) 1.15
cAMP inducibility of transcriptional repressor ICER in developing and mature human T lymphocytes. Proc Natl Acad Sci U S A (1996) 1.12
Prostaglandin E2 and other cyclic AMP elevating agents inhibit interleukin 2 gene transcription by counteracting calcineurin-dependent pathways. J Exp Med (1993) 1.07
Isolation of nuclear extracts from fragile cells: a simplified procedure applied to thymocytes. Biotechniques (1994) 1.02
c-Jun N-terminal kinase but not mitogen-activated protein kinase is sensitive to cAMP inhibition in T lymphocytes. J Biol Chem (1995) 1.02
Interaction of CD2 with its ligand lymphocyte function-associated antigen-3 induces adenosine 3',5'-cyclic monophosphate production in T lymphocytes. J Immunol (1991) 0.98
The CD3 zeta cytoplasmic domain mediates CD2-induced T cell activation. J Exp Med (1992) 0.96
Differential activation of viral and cellular promoters by human T-cell lymphotropic virus-1 tax and cAMP-responsive element modulator isoforms. J Biol Chem (1997) 0.95
The lymphocyte-specific tyrosine protein kinase p56lck is endocytosed in Jurkat cells stimulated via CD2. J Immunol (1992) 0.92
Activation of type I protein kinase A during receptor-mediated human T lymphocyte activation. J Immunol (1996) 0.88
CD2 signaling in T cells involves tyrosine phosphorylation and activation of the Tec family kinase, EMT/ITK/TSK. Int Immunol (1996) 0.88
Regulation of cAMP-responsive enhancer binding proteins during cell cycle progression in T lymphocytes stimulated by IL-2. J Immunol (1995) 0.88
Late induction of CREB/ATF binding and a concomitant increase in cAMP levels in T and B lymphocytes stimulated via the antigen receptor. J Immunol (1996) 0.86
Signaling via the CD2 receptor enhances HTLV-1 replication in T lymphocytes. Virology (1997) 0.85
CD3-dependent increase in cyclic AMP in human T-cells following stimulation of the CD2 receptor. Biochim Biophys Acta (1991) 0.79
Mitogen activation of human peripheral T lymphocytes induces the formation of new cyclic AMP response element-binding protein nuclear complexes. J Biol Chem (1994) 0.78
Cyclic AMP-mediated growth arrest is associated with increased expression of human T cell leukemia virus type I structural and transforming genes. AIDS Res Hum Retroviruses (1996) 0.78
Stimulation of the CD2 receptor pathway induces apoptosis in human T lymphotropic virus type I-infected cell lines. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 0.77
Tyrosine phosphorylation and recruitment of ZAP-70 to the CD3-TCR complex are defective after CD2 stimulation. J Immunol (1996) 0.77
Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J Exp Med (1998) 2.49
Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo. Blood (1998) 2.03
Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol (1996) 1.88
Functional role of pX open reading frame II of human T-lymphotropic virus type 1 in maintenance of viral loads in vivo. J Virol (2000) 1.61
Rhesus monkey model for fetal gene transfer: studies with retroviral- based vector systems. Mol Ther (2001) 1.53
Serological confirmation of human T-lymphotropic virus type I infection in healthy blood and plasma donors. Blood (1989) 1.47
Human T-lymphotropic virus type 1 p30(II) regulates gene transcription by binding CREB binding protein/p300. J Virol (2001) 1.42
Characterization of antibody reactivity to human T-cell lymphotropic virus types I and II using immunoblot and radioimmunoprecipitation assays. J Clin Microbiol (1990) 1.40
Human T-lymphotropic virus type 1 open reading frame I p12(I) is required for efficient viral infectivity in primary lymphocytes. J Virol (2000) 1.34
In vitro CD4+ lymphocyte transformation and infection in a rabbit model with a molecular clone of human T-cell lymphotrophic virus type 1. J Virol (1996) 1.33
Human T-lymphotropic virus type 1 p30(II) functions as a transcription factor and differentially modulates CREB-responsive promoters. J Virol (2000) 1.31
Human T-cell lymphotropic virus type 1 Tax mediates enhanced transcription in CD4+ T lymphocytes. J Virol (1996) 1.22
Endoplasmic reticulum and cis-Golgi localization of human T-lymphotropic virus type 1 p12(I): association with calreticulin and calnexin. J Virol (2001) 1.18
Comparative analysis of nucleotide sequences of the partial envelope gene (5' domain) among human T lymphotropic virus type I (HTLV-I) isolates. Virology (1991) 1.16
Experimental coinduction of type D retrovirus-associated pulmonary carcinoma and lentivirus-associated lymphoid interstitial pneumonia in lambs. J Natl Cancer Inst (1987) 1.16
HTLV-I-associated myelopathy associated with blood transfusion in the United States: epidemiologic and molecular evidence linking donor and recipient. Neurology (1991) 1.14
Differential replication and pathogenic effects of HIV-1 and HIV-2 in Macaca nemestrina. AIDS (1994) 1.10
Ovine lentivirus lymphoid interstitial pneumonia. Rapid induction in neonatal lambs. Am J Pathol (1986) 1.08
Proliferation response to interleukin-2 and Jak/Stat activation of T cells immortalized by human T-cell lymphotropic virus type 1 is independent of open reading frame I expression. J Virol (1999) 1.07
Three primary neoplasms in a goat: hepatocellular carcinoma, phaeochromocytoma and leiomyoma. J Comp Pathol (1987) 1.05
The etiology and pathogenesis of ovine pulmonary carcinoma (sheep pulmonary adenomatosis). Vet Microbiol (1988) 1.05
CCAAT/enhancer-binding protein delta regulates mammary epithelial cell G0 growth arrest and apoptosis. J Biol Chem (1999) 1.01
Quantification of human T-cell lymphotropic virus type 1 proviral load by quantitative competitive polymerase chain reaction. J Virol Methods (1998) 1.01
Enhanced human T-cell lymphotropic virus type I expression following induction of the cellular stress response. Virology (1995) 0.98
Serologic discrimination of human T cell lymphotropic virus infection by using a synthetic peptide-based enzyme immunoassay. J Infect Dis (1991) 0.98
In vitro cellular tropism of human T cell leukemia virus type 2. AIDS Res Hum Retroviruses (2000) 0.98
Evaluation of enzyme immunoassays for antibody to human T-lymphotropic viruses type I/II. Lancet (1991) 0.94
HTLV-I-associated myelopathy endemic in Texas-born residents and isolation of virus from CSF cells. Neurology (1991) 0.94
Humoral hypercalcemia of malignancy: severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression. Am J Pathol (2001) 0.93
The cellular stress response enhances human T-cell lymphotropic virus type 1 basal gene expression through the core promoter region of the long terminal repeat. J Virol (1997) 0.92
Retrovirus-associated ovine pulmonary carcinoma (sheep pulmonary adenomatosis) and lymphoid interstitial pneumonia. I. Lesion development and age susceptibility. Vet Pathol (1988) 0.91
The human T-cell leukemia virus type 1 p13II protein: effects on mitochondrial function and cell growth. Cell Death Differ (2005) 0.91
Lymphangiosarcoma in a young dog. Vet Pathol (1996) 0.90
Soluble recombinant HTLV-1 surface glycoprotein competitively inhibits syncytia formation and viral infection of cells. Virus Res (2001) 0.90
Analysis of antibody responses to phenotypically distinct lentiviruses. J Clin Microbiol (1990) 0.90
Simian immunodeficiency virus needlestick accident in a laboratory worker. Lancet (1992) 0.89
Mouse models of human T lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma. Vet Pathol (2010) 0.88
Lesions and retroviruses associated with naturally occurring ovine pulmonary carcinoma (sheep pulmonary adenomatosis). Vet Pathol (1988) 0.87
Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia/lymphoma. Leukemia (2005) 0.86
Signaling via the CD2 receptor enhances HTLV-1 replication in T lymphocytes. Virology (1997) 0.85
Transcriptional modulation of viral reporter gene constructs following induction of the cellular stress response. Nucleic Acids Res (1997) 0.84
The margin of safety of a single application of transdermal fentanyl solution when administered at multiples of the therapeutic dose to laboratory dogs. J Vet Pharmacol Ther (2012) 0.83
Differential induction of tumor necrosis factor alpha in ovine pulmonary alveolar macrophages following infection with Corynebacterium pseudotuberculosis, Pasteurella haemolytica, or lentiviruses. Infect Immun (1991) 0.83
Infectious transmission of human T-cell lymphotropic virus type II in rabbits. Blood (1991) 0.83
Characterization of a HTLV-I-infected cell line derived from a patient with adult T-cell leukemia with stable co-expression of CD4 and CD8. Leuk Res (1995) 0.83
Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. J Vet Pharmacol Ther (2012) 0.82
Pharmacokinetics and the effect of application site on a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. J Vet Pharmacol Ther (2012) 0.82
The safety and effectiveness of a long-acting transdermal fentanyl solution compared with oxymorphone for the control of postoperative pain in dogs: a randomized, multicentered clinical study. J Vet Pharmacol Ther (2013) 0.82
Familial adult T-cell leukemia/lymphoma. Am J Hematol (1990) 0.82
The effectiveness of a long-acting transdermal fentanyl solution compared to buprenorphine for the control of postoperative pain in dogs in a randomized, multicentered clinical study. J Vet Pharmacol Ther (2012) 0.82
Pathogenesis of lymphoid interstitial pneumonia in natural and experimental ovine lentivirus infection. Clin Infect Dis (1993) 0.81
Serologic confirmation of simian T-lymphotropic virus type I infection by using immunoassays developed for human T-lymphotropic virus antibody detection. J Clin Microbiol (1992) 0.81
Effects of whole blood lysis and fixation on the infectivity of human T-lymphotropic virus type 1 (HTLV-I). Cytometry (1994) 0.81
Oxytetracycline-associated nephrotoxicosis in feedlot calves. J Am Vet Med Assoc (1984) 0.81
Detection of simian T-lymphotropic virus type I using the polymerase chain reaction. Int J Cancer (1992) 0.80
Repression of tax-mediated human t-lymphotropic virus type 1 transcription by inducible cAMP early repressor (ICER) protein in peripheral blood mononuclear cells. J Med Virol (2000) 0.80
Constitutive expression of c-jun and jun-B in cell lines infected with human T-lymphotropic virus types I and II. Biochem Biophys Res Commun (1991) 0.80
The effect of the cellular stress response on human T-lymphotropic virus type I envelope protein expression. J Gen Virol (1998) 0.79
Cellular immunity in dogs with keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. Vet Immunol Immunopathol (1995) 0.79
Comparison of HTLV-I basal transcription and expression of CREB/ATF-1/CREM family members in peripheral blood mononuclear cells and Jurkat T cells. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 0.79
Population pharmacokinetics of transdermal fentanyl solution following a single dose administered prior to soft tissue and orthopedic surgery in dogs. J Vet Pharmacol Ther (2012) 0.79
Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I). Biomed Pept Proteins Nucleic Acids (1995) 0.78
Epidemiologic assessment of screening tests for antibody to human T lymphotropic virus type I (HTLV-I). Am J Public Health (1990) 0.78
Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide. Vaccine (2000) 0.78
Sexual transmission of simian T-lymphotropic virus type I: a model of human T-lymphotropic virus type I infection. Leukemia (1994) 0.77
Immune recognition of genetically diverse simian T-cell lymphotropic virus type I isolates. Arch Virol (1995) 0.77
HTLV-I in Alaska Natives. J Acquir Immune Defic Syndr (1993) 0.77
Naloxone reversal of an overdose of a novel, long-acting transdermal fentanyl solution in laboratory Beagles. J Vet Pharmacol Ther (2012) 0.77
Stimulation of the CD2 receptor pathway induces apoptosis in human T lymphotropic virus type I-infected cell lines. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 0.77
Prevalence of HTLV-I in Alaska Natives. J Infect Dis (1990) 0.76
Concomitant augmentation of CD4+ CD29+ helper inducer and diminution of CD4+ CD45RA+ suppressor inducer subset in patients infected with human T cell lymphotropic virus types I or II. Clin Exp Immunol (1992) 0.76
Seroprevalence of human T lymphotropic virus type I in Puerto Rico. Am J Trop Med Hyg (1989) 0.75
Atypical human T-cell lymphotropic virus type-I-associated T-cell lymphoma in a low-prevalence Alaska Native population. Implications for disease surveillance. Cancer (1993) 0.75
Prospects for a human immunodeficiency virus/AIDS vaccine. Dev Biol Stand (1990) 0.75
Preliminary analysis of the polypeptides of the salmon leukemia virus (SLV) and evidence for development of a bimodal viremia following SLV infection. Vet Microbiol (1994) 0.75
Glycosylation-dependent peptide antigenic determinants of env gp46 HTLV-1. Leukemia (1995) 0.75
Co-stimulation of human peripheral blood mononuclear cells with IL-2 and anti-CD3 monoclonal antibodies induces phosphorylation of CREB. Immunol Lett (1998) 0.75
Comparative biological features of a rat liver abscess model induced with three Fusobacterium necrophorum strains. Am J Vet Res (1983) 0.75